PUBLIC COMPANY
save$EYPTEyePoint, Inc.
$EYPT5.4000-14.29%Watertown, MA, USupdated 11h ago
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 17, 26option exerciseRibeiro Ramiro · Chief Medical Officer2,437 sh
- Apr 17, 26option exerciseRibeiro Ramiro · Chief Medical Officer2,437 sh
- Mar 23, 26otherDuker Jay S. · President and CEO76,766 sh
- Mar 23, 26otherDuker Jay S. · President and CEO76,766 sh
- Mar 23, 26otherDuker Jay S. · President and CEO97,500 sh
- Mar 23, 26otherDuker Jay S. · President and CEO97,500 sh
🐶 Hiring Signal
News
- EyePoint’s bid to compete with Eylea falls flatEyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…endpoints · 3d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that